Instil Bio, Inc.
TIL
Rank in Stocks
#23279
Instil Bio, Inc. operates as a clinical-stage biopharmaceutical firm,... Instil Bio, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating its efforts on devising novel therapeutic options for individuals battling cancer. A cornerstone of their research involves the advancement of autologous tumor-infiltrating lymphocyte (TIL) cell therapies. Their developmental portfolio features ITIL-168, currently under investigation for a range of malignancies including melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer. Another promising candidate, ITIL-306, is engineered to identify folate receptor alpha (FOLR1) and is being explored for gynecological cancers, non-small cell lung cancer, renal cancer, and other conditions. This company was founded in 2018 and has its principal office situated in Dallas, Texas.
Share Price
$6.47
Last synced: 2026-11-09
Market Cap
$43.88M
Change (1 day)
-5.27%
Change (1 year)
-58.92%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Instil Bio, Inc. (TIL)
Category
Healthcare
EPS for Instil Bio, Inc. (TIL)
EPS as of June 2026 TTM: $-4.47
According to Instil Bio, Inc.'s latest financial reports, its current EPS (TTM) is $-4.47. At the end of 2025 the company had an EPS of $-10.70, an increase over its 2024 EPS of $-11.39.
EPS history for Instil Bio, Inc. from 2019 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-4.47 | -58.22% |
| 2025 | $-10.70 | -6.06% |
| 2024 | $-11.39 | -52.54% |
| 2023 | $-24.00 | -30.35% |
| 2022 | $-34.46 | 16.42% |
| 2021 | $-29.60 | 402.55% |
| 2020 | $-5.89 | 483.17% |
| 2019 | $-1.01 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -450.34% |
US
|
|
| $-7.07 | 58.17% |
US
|
|
| $-5.29 | 18.34% |
AU
|
|
| $12.88 | -388.15% |
BE
|
|
| $21.56 | -582.33% |
NL
|
Questions about Instil Bio, Inc.'s earnings per share (EPS)
What is Instil Bio, Inc.'s earnings per share (EPS)?
Instil Bio, Inc.'s earnings per share (EPS) over the last twelve months is $-4.47, as of Jun 2026.
What was Instil Bio, Inc.'s earnings per share (EPS) in 2025?
In 2025, Instil Bio, Inc.'s earnings per share (EPS) was $-10.70, compared with $-11.39 in 2024.
How has Instil Bio, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Instil Bio, Inc.'s earnings per share (EPS) was highest in 2020 ($-5.89) and lowest in 2022 ($-34.46).
How does Instil Bio, Inc.'s earnings per share (EPS) compare with similar companies?
Instil Bio, Inc.'s earnings per share (EPS) ($-4.47) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.